NC-762 is under clinical development by NextCure and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NC-762’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NC-762 is under development for the treatment of solid tumors including non-small cell lung cancer, HER2 positive breast cancer, melanomat, endometrial cancer, pancreatic cancer, prostate cancer and ovarian cancer. It is administered through intravenous route. The therapeutic candidate is development is based on functional, integrated, next cure discovery in immuno-oncology (FIND-IO) technology platform. It acts by targets B7-H4.
NextCure is biopharmaceutical company that develops immune medicines to treat cancer and other immune-related diseases. The company’s product portfolio includes FIND-IO technology platform to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its pipeline products include protein drugs such as NC762, NC525 and NC410 are expressed on highly immunosuppressive cells and tumor cells. It is also pursuing partnering opportunities with pharmaceutical and biotechnology companies to discover and develop biologic-based therapeutics for the treatment of cancer, autoimmune, neurological disorders and expanding to a variety of therapeutic areas. NextCure is headquartered in Beltsville, Maryland, the US.
For a complete picture of NC-762’s drug-specific PTSR and LoA scores, buy the report here.